Table 5.
Summary of case-control studies of endoresection for uveal melanoma.
| Author | Treatment | Pts, n |
Diameter, mm |
Thickness | Follow-Up, mean | Survival | Enucleation | Recurrence | VA, Pre-Treatment |
VA, Post-Treatment |
Complications |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Caminal et al., 2013 [29] | Endoresection (no BT adjuvant) | 27 | 11 (IQR 2.9) | 7.69 (IQR 2.27) | 59.37 (12–138) |
3.7% (1/27) metastasis 3.7% specific death 100% at 5 years (K-M) cause-specific survival |
11.1% (3 pts) 87.8% at 5 years (K-M) |
7.4% (2 pts) 92.4% at 5 years (K-M) |
0.2 | 22.2% 20/200 or better KM probability of maintaining a VA equal or superior to 20/200 at 5 years was 59.9% |
|
| BT | 54 | 12.5 (IQR 2.0) | 6.95 (IQR1.8) | 70.52 (12–148) | 20.4% (11 pts) 18.5% specific death 84.2% at 5 years (K-M) cause-specific survival |
13% (7 pts) 85.7% at 5 years (K-M) |
1.8% (1 pts) 96.6% at 5 years (K-M) |
35.2% 20/200 or better KM probability of maintaining a VA equal or superior to 20/200 at 5 years was 66.4% group and 59.9% in the endoresection group |
|||
| Rice et al., 2014 [30] | Endoresection (BT adjuvant) |
22 | 11.2(3.4–16.0) | 7.3 mm (3.0–10.0) | 62.4 (7.9–121.8) | 18.2% metastasis 20.4% died |
4.6% (1 pts) | 18.2% (4 pts) | Snellen ±6/24 | ±6/50 6/18 or better in 41% of endoresection group and 35% of the BT group retained vision of 6/18 or better at the end of follow-up. Eight out of 22 (36%) endoresection and 68/142 (48%) BT had 2/60 or worse at the last visit |
|
| BT | 148 | 10.3 mm (range 4.5–16.0) | 4.9 mm (range 2.5–10.0 | 55.4 (6.6–175.8) | 14.2% | 10.8% | Local recurrence rate higher in endoresection group (18.2% vs. 14.9%, p = 0.75) but not significant. |
Abbreviations: IQR, interquartile range; pts, patients; BT, brachytherapy; CME: cystoid macular edema; CNVM: Choroidal neovascular membrane; ERM: epiretinal membrane; PRP: postradiation retinopathy; VH: vitreous hemorrhage; pts, patients.